Abstract

Research Article

Estimation of Serum Beta 2- microglobulin among newly diagnosed children with cancer in Basra

Ahmed Mohsin Aziz and Janan Ghalib Hasan*

Published: 10 May, 2018 | Volume 2 - Issue 1 | Pages: 022-035

Background: Beta 2- micro globulin (β2-MG) is involved in human malignancies. Increased synthesis and release of β2-MG, as indicated by elevated serum, plasma, or urine β2-MG concentration, occurs in several malignant diseases.

Objective: The study was designed to assess the role of serum Beta2- micro globulin in the support of the diagnosis of different types of pediatric malignancies.

Subjects and Methods: This case - control study was carried out on 137 children and adolescents with newly diagnosed pre-treated malignant diseases who were admitted to pediatric oncology center at Basra Children’s Specialty Hospital, their ages ranged from 3 months to 15 years, during the period from the 1st of November 2014 till the end of October 2015, 71 were males and 66 were females and 148 healthy children and adolescents (83 were males and 65 were females) matched for age and sex regarded as control group. Cases and control characteristics were assessed from data collection by special questionnaire. All patients and control group were investigated for Beta2- microglobulin by the enzyme-linked immunosorbent assay.

Results: The study had revealed that level of Beta2-microglobulin was significantly higher in patients with malignancy in comparison to control group, P value < 0.001.Also the serum Beta2- microglobulin level for both hematological malignancies and solid malignancies was assessed and it was found that significantly higher percentage of elevated serum Beta2- microglobulin level was present in patients with hematological malignancies in comparison to solid malignancies, P value <0.01.The study also had revealed that there was a significant correlation between the initial white blood cells count ≥ 50000 cells/ml and abnormal serum Beta2- microglobulin level, P value < 0.01,but there was no significant differences in serum Beta2- microglobulin level in relation to risk groups and immunophynotypes of acute lymphoblastic leukemia ,morphological subtypes of acute myloid leukemia, stages of each type of lymphoma (Hodgkin lymphoma and non-Hodgkin lymphoma) and the histopathological subtypes of non-Hodgkin lymphomas. After subjecting variables (specific to acute lymphoblastic leukemia) to logistic regression analysis, the significant independent risk factor that associated with abnormal serum Beta2- microglobulin level was high initial white blood cells count (≥50000 cells/ml).

Conclusion: Serum Beta2- microglobulin level is significantly higher in patients with hematological malignancies and high initial white blood cells count(≥50000cells/ml) .From this study, serum Beta2- microglobulin could be recommended in the initial work up for diagnosis of childhood malignancy.

Read Full Article HTML DOI: 10.29328/journal.jro.1001018 Cite this Article Read Full Article PDF

Keywords:

Children with cancer; Beta 2- macroglobulin; Basra Pediatric Oncology Center; Iraq

References

  1. Stiller C, Draper G. The epidemiology of cancer in children. In: Voute P, Barrett A, Stevens M, Caron H. Cancer in Children Clinical Management; 5th Edition. Oxford University Press. 2005; 2-16.
  2. Nomura T, Huang W, Josson S, Mimata H, Zhau H, et al. β2-microglobulin-mediated Signaling as a Target for Cancer Therapy. Anticancer Agents Med Chem. 2014; 14: 343-352. Ref.: https://goo.gl/HYPHp7
  3. Menegaux F, Bertrand Y, Lescoeur B, Leverger G, Nelken B, et al. Household Exposure to Pesticides and Risk of Childhood Acute Leukemia. Occup Environ Med. 2006; 63: 131-134. Ref.: https://goo.gl/od3J6A
  4. Imbach P. General Aspects of Childhood Leukemia. In: Imbach P, Kühne Th, Arceci R (Eds). Pediatric Oncology a comprehensive Guide; 4th edition. Germany. Springer-Verlag Berlin Heidelberg. 2006: 5-9.
  5. Rytting M, Choroszy M, Petropoulos D, Chan K. Acute Leukemia In: Aman U, Ralph S. Pediatric Oncology.United States of America. Springer Science Business Media. 2005; 1-16.
  6. Al-Mukhtar M, Muzahim H, Alsaraji M, Husain A, Jasim K, et al. Iraqi Cancer Registry, Iraq Cancer Board, Ministry of Health. 2011; 2: 140-147.
  7. Asselin B. Epidemiology of Childhood and Adolescent Cancer. In: Behrman E, Kliegman RM, Jenson HB (eds). Nelson Textbook of Pediatrics; 20th edition. Philadelphia. Elsevier Saundrers co. 2015; 2416-2418.
  8. Scheurer M, Bondy M, Gurney J. Epidemiology of Childhood Cancer. In: Pizzo PA, Poplack DG, (eds). Principles and practice of pediatric oncology; 6th edition. Philadelphia. Lippincott Williams and Wilkins. 2010; 3-16.
  9. Tubergen D, Bleyer A, Ritchey A. The Leukemias. In:Behrman E, Kliegman RM, Jenson HB (eds). Nelson Textbook of Pediatrics; 20th edition. Philadelphia. Elsevier Saundrers co. 2015; 2437-2442. Ref.: https://goo.gl/h3egaW
  10. Redner A, MD. Leukemias. In: Lanzkowsky P editor. Manual of Pediatric Hematology and Oncology; 5th edition. London. Elsevier. 2011; 519-566. Ref.: https://goo.gl/eRCRB1
  11. Smith OP, Hann I. Pathology of leukemia. In: Pinkerton R, Plowman PN, Pieter R. Pediatric oncology; 3rd edition. London Arnold CO. 2004; 83-100.
  12. Margolin Rabin JK, Steuber C, Poplack Philip SD, David G. Acute Lymphoblastic Leukemia. In: PizzoPA, Poplack DG, (eds). Principles and practice of pediatric oncology; 6th edition. Philadelphia. Lippincott Williams and Wilkins. 2010; 519-565.
  13. Dunn I, Hahn W. Molecular Basis of Human Malignancy. In : Orkin S, Fisher D, Thomas look A, Lux S, Ginsburg D, Nathan D. Oncology of infancy and childhood; 1st edition. Philadelphia. Elsevier Saunders. 2009; 41-55.
  14. Imbach P. Acute Lymphoblastic Leukemia. In: Imbach P, Kühne Th, Arceci R (Eds.).Pediatric Oncology A Comprehensive Guide; 4th edition. Germany. Springer-Verlag Berlin Heidelberg. 2006; 11-27.
  15. Schmiegelow K, Gustafsson G. Acute Lymphoblastic Leukemia. In: Voute P, Barrett A, Stevens M, Caron H. Cancer in Children Clinical Management; 5th Edition. Oxford University Press. 2005; 139 -170.
  16. Cooper T, Hasle H, Smith F. Acute Myeloid Leukemia, Myeloproliferative and Myelodysplastic Disorders. In: Pizzo PA, Poplack DG, (eds). Principles and practice of pediatric oncology; 6th Edition. Philadelphia. Lippincott Williams and Wilkins. 2010; 567-610.
  17. Gibson B, Shenton G. Acute Myeloid Leukemia. In: Voute P, Barrett A, Stevens M, Caron H. Cancer in Children Clinical Management; 5th Edition. Oxford University Press. 2005; 172-185.
  18. Zwaan M, van den Heuvel-Eibrink M. Pediatric Acute Myeloid Leukemia, Acute Leukemia - The Scientist's Perspective and Challenge, Prof. Mariastefania Antica (Ed.).
  19. Stiller CA. Aetiology and epidimiology. In: Pinkerton R, Plowman PN, Pieter R (eds). Pediatric oncology; 3rd edition. London. Arnold CO. 2004; 3-24.
  20. Meschinchi S, Arceci RJ. Prognostic factors and risk based therapy in pediatric acute myeloid leukemia. Oncologist. 2007; 12: 341-355. Ref.: https://goo.gl/7HHnnJ
  21. Nicholson H. Hodgkin Disease. In: Elzouki A, Harfi H, Nazer H, Stapleton F, William O, Whitley R .Textbook of Clinical Pediatrics; Second Edition. Springer-Verlag Berlin Heidelberg. 2012; 3207-3209.
  22. Hastings C, Torkildson J, Agrawal A. Hodgkin and non-Hodgkin lymphoma. In: Hastings C, Torkildson J, Agrawal A. Handbook of Pediatric Hematology and Oncology: Children’s Hospital & Research Center Oakland; Second Edition.UK. Wiley-Blackwell. 2012; 166-173.
  23. Kline N, Sevier N. Solid tumor in children. J Pediatric Nursing. 2003; 18: 96-102. Ref.: https://goo.gl/JnHdPV
  24. Kieran M, Chi S, Samuel D, Lechpammer M, Blackman S, et al. Tumors of the Brain and Spinal Cord. In: Orkin S, Fisher D, Look A, Lux IV S, Ginsburg D et al (Eds). Oncology of infancy and childhood; 1st edition .Philadelphia. Elsevier Saunders. 2009; 601-720.
  25. Ater J. Medulloblastoma and Glioma. In: Pinkerton, Shankar A, Matthay K.Evidence-based Pediatric Oncology; Second Edition. USA Blackwell Publishing. 2007; 125-161.
  26. Macdonald T. Pediatric cancer: Acomprehensive review. Part 1: Biology, epidemiology, common tumours, principle of treatment and late effect. Can pharm J. 2010; 143: 176-183. Ref.: https://goo.gl/FYLTxD
  27. Matthay K. Neuroblastoma. In: Pinkerton R, AG Shankar A, Matthay K. Evidence-based Pediatric Oncology; Second Edition. USA Blackwell Publishing. 2007; 93-114. Ref.: https://goo.gl/ceG1az
  28. Hastings C, Torkildson J, Agrawal A. Wilms tumor. In: Hastings C, Torkildson J, Agrawal A. Handbook of Pediatric Hematology and Oncology: Children’s Hospital & Research Center Oakland; Second Edition.UK. Wiley-Blackwell. 2012; 174-177. Ref.: https://goo.gl/SzVyWW
  29. Kiss S, Leiderman YI, Mukai S. Diagnosis, classification and treatment of retinoblastoma. Int Ophthalmology Clinic. 2008; 48: 135-147. Ref.: https://goo.gl/wNJTJG
  30. Breitfeld P, Grier HE. Rhabdomyosarcoma. In: Rudolph C, Rudolph A. (eds). Rudolph’s Pediatrics; 21st Edition. Copyright © McGraw-Hill. 2003; 1613-1615.
  31. Makin G, Meyer S. Oncology In: McIntosh N, Helms P, Smyth R, Logan S. Forfar & Arneil’s TEXTBOOK of PEDIATRICS; Seventh Edition. Toronto. Churchill Livingstone Elsevier. 2008; 991-1038.
  32. Kapoor G, Jain S, Tiwari A. Ewing sarcoma: Current Concepts and Surgical Control. In: Hayat M.A. (eds). Pediatric Cancer Diagnosis, Therapy, and Prognosis; volume4. NewYork. Springer Dordrecht. Heidelberg. 2013; 227-235. Ref.: https://goo.gl/PBpL15
  33. Bethea M, Forman DT. Beta 2-microglobulin: its significance and clinical usefulness. Ann Clin Lab Sci. 1990; 20: 163-168. Ref.: https://goo.gl/8YoKdH
  34. Bicknell D, Rowan A, Bodmer W. β 2-microglobulin gene mutations: a study of established colorectal cell lines and fresh tumors. Proc Natl Acad Sci U S A. 1994; 91: 4751-4755. Ref.: https://goo.gl/VrAKFa
  35. Ouwehand W, Navarrete C. The molecular basis of blood cell alloantigens. In: Provan D, Gribben J Molecular Hematology. 2005; 225-240.
  36. Drayson M, Moss P. Normal lymphocytes and non-neoplastic lymphocyte Disorders.In:Hoffbrand A,Catovsky D,Tuddenham E.Postgraduate Haematology; 5th Edition. Victoria. Blackwell Publishing. 2005; 330-357. Ref.: https://goo.gl/owTLgN
  37. Hibi Y, Uemura O, Nagai T. The ratios of urinary β2-microglobulin and NAG to creatinine vary by age in children. Pediatr Int. 2014; 57: 79-84. Ref.: https://goo.gl/3fXB7y
  38. Floege J, Ketteler M. Beta2-microglobulin-derived amyloidosis: an update. Kidney Int Suppl. 2001; 78: 164- 171. Ref.: https://goo.gl/Moc9As
  39. Huang W, Have J, Zhan H, Qian W, Lue H, et al. β2- microglobulin Signaling Blockade Inhibited Androgen Receptor Axis and Caused Apoptosis in Human Prostate Cancer Cells. HHS Public Access. Clin Cancer Res. 2008; 14: 5341-5347. Ref.: https://goo.gl/112zWA
  40. Huang W, Zhau H, Chung L. Androgen Receptor Survival Signaling Is Blocked by Anti-β2-microglobulin Monoclonal Antibody via a MAPK/Lipogenic Pathway in Human Prostate Cancer Cells. J Biological Chem. 2010; 285: 7947-7956. Ref.: https://goo.gl/sQmua7
  41. Mangione P, Esposito G, Relini A, Raimondi S, Porcari R, et al. Structure, folding dynamics, and amyloidogenesis of D76N β2-microglobulin: roles of shear flow, hydrophobic surfaces, and a-crystallin. J Biological Chem. 2013; 288: 30917-30930. Ref.: https://goo.gl/yVnQhv
  42. Goodman H, Hawkins P. Amyloidosis. In: Hoffbrand A, Catovsky D, Tuddenham E. Postgraduate Haematology; 5th Edition .Victoria. Blackwell Publishing. 2005; 703-713.
  43. Svatoňová J, Bořecká K, Adam P, Lánská V. Beta2-microglobulin as a Diagnostic Marker in Cerebrospinal Fluid: A Follow-Up Study. Hindawi Publishing Corporation. Disease Markers. 2014; 1-6. Ref.: https://goo.gl/WJDM9t
  44. Rodriguez J, Cortes J, Talpaz M, Brien S ,Smith T, et al. Serum β2- microglobulin Levels Are a Significant Prognostic Factor in Philadelphia Chromosome-positive Chronic Myelogenous Leukemia. Clin Cancer Res. 2000; 6: 147-152. Ref.: https://goo.gl/QJQwyH
  45. Al-Rubaye F, Abdul- Jalil F, Waheed T, Abbas S. Correlation of Serum Concentration of Cystatin C & β2-microglobulin in Pediatric Malignancy. Iraqi J Comm Med. 2012; 1: 28-31. Ref.: https://goo.gl/WLJPnE
  46. Nomura T, Huang W, Zhau H, Xie Z, Mimata H, et al. β 2-microglobulin Promotes the Growth of Human Renal Cell Carcinoma through the Activation of the Protein Kinase A , Cyclic AMP Responsive Element-Binding Protein, and Vascular Endothelial Growth Factor Axis. Human Cancer Biology Clin Cancer Res. 2006; 12: 7294-7305. Ref.: https://goo.gl/41XxJp
  47. Zhu Y, Su Y, Cheng T, Chung L, Shi C. β2-microglobulin as a potential factor for the expansion of mesenchymal stem cells. NIH Public Access. 2009; 31: 1361-1365. Ref.: https://goo.gl/BhCfq3
  48. Bien E, Balcerska A, Ciesielski D. Serum β2-microglobulin levels at diagnosis and during antitumour treatment in children with malignant neoplasms. Nowotwory Journal of Oncology. 2005; 55: 34-38. Ref.: https://goo.gl/S2KAFe
  49. Anderson K, Pazdur R, Farrell A. Multiple myeloma and related disorders. In. Hoffbrand A, Moss P, Pettit J. Essential Haematology; 5th Edition. Massachusetts. Blackwell Publishing. 2006; 216- 229.
  50. Yang J, Qian J, Wezeman M, Wang S, Lin P, et al. Targeting beta2-microglobulin for induction of tumor apoptosis in human hematological malignancies. Cancer Cell. 2006; 10: 295-307. Ref.: https://goo.gl/GnW7sx
  51. Cooper M, Hutchins G, Mennie R, Israel M. β2-microglobulin Expression in Human Embryonal Neuroblastoma Reflects Its Developmental Regulation (CANCER RESEARCH). 1990; 50: 3694-3700. Ref.: https://goo.gl/Fw4VWo
  52. Josson S, Nomura T, Lin J, Huang W, Wu D, et al. β2-microglobulin Induces Epithelial to Mesenchymal Transition and Confers Cancer Lethality and Bone Metastasis in Human Cancer Cells. Molecular and Cellular Pathobiology. Cancer Res. 2011; 71: 2600-2610. Ref.: https://goo.gl/HBkj1h
  53. Janeway KA. Non-Hodgkin Lymphoma In: Lanzkowsky P editor. Manual of Pediatric Hematology and Oncology; 5th edition. London. Elsevier. 2011; 624-646.
  54. Martincu R, Ionita H. Beta 2 -microglobuline biological marker with diagnostic and prognosis value in multiple myeloma. TMJ. 2007; 57: 29-32. Ref.: https://goo.gl/oiNQRt
  55. Balcerska A, Bień E, Ciesielski D. Does beta 2-microglobulin measurement play role in diagnostics of childhood malignancies. Wiad Lek. 2004; 57: 8-11. Ref.: https://goo.gl/LXALNw
  56. Federico M, Guglielmi C, Luminari S, Mammi C, Marcheselli L, et al. Prognostic Relevance Of Serum β2- microglobulin In Patients With Follicular Lymphoma Treated With Anthracycline-Containing Regimens. A GISL Study Haematologica Journal of European Hematology Association. 2007; 92: 1482-1488. Ref.: https://goo.gl/r9XvbR
  57. Tsimberidou A, Kantarjian H, Brien S, Cortes J, Wierda W, et al. The Prognostic Significance of Serum β2- microglobulin Levels in Acute Myeloid Leukemia and Prognostic Scores Predicting Survival: Analysis of 1, 180 Patients. Clin Cancer Res. 2008; 14: 721-730. Ref.: https://goo.gl/8ADKDK
  58. Bien E, Balcerska A. Serum Soluble Interleukin-2 Receptor, beta2-microglobulin, Lactate Dehydrogenase and Erythrocyte Sedimentation Rate in Children with Hodgkin’s Lymphoma. Scand J Immunol. 2009; 70: 490-500. Ref.: https://goo.gl/TrH8Gs
  59. Mazher N, Iqbal Z , Aslam N, Mazher S. Beta2-microglobulin as a marker of extent of disease in non-Hodgkin lymphoma. Biomedica. 2010; 26: 1-4. Ref.: https://goo.gl/aJeQGr
  60. Al-Barazanchi Z, Al-Ali J, Al-Abbadi A. Beta2 -microglobulin: a novel bio-marker assisting in the diagnosis of lymphoma: A study of 669 newly diagnosed lymphoma cases in the South of Iraq. Basrah Journal of Surgery. 2014; 20: 90-95.

Similar Articles

Recently Viewed

Read More

Most Viewed

Read More

Help ?